Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia.

We report preclinical proof of principle for effective treatment of B-precursor acute lymphoblastic leukemia (ALL) by targeting the spleen tyrosine kinase (SYK)–dependent antiapoptotic blast cell survival machinery with a unique nanoscale pharmaceutical composition. This nanoscale liposomal formulation (NLF) contains the pentapeptide mimic 1,4-Bis (9-O dihydroquinidinyl) phthalazine/hydroquinidine 1,4-phathalazinediyl diether (C61) as the first and only selective inhibitor of the substrate binding P-site of SYK. The C61 NLF exhibited a very favorable pharmacokinetic and safety profile in mice, induced apoptosis in primary B-precursor ALL blast cells taken directly from patients as well as in vivo clonogenic ALL xenograft cells, destroyed the in vivo clonogenic fraction of ALL blast cells, and, at nontoxic dose levels, exhibited potent in vivo antileukemic activity against patient-derived ALL cells in xenograft models of aggressive B-precursor ALL. Our findings establish SYK as an attractive molecular target for therapy of B-precursor ALL. Further development of the C61 NLF may provide the foundation for therapeutic innovation against therapy-refractory B-precursor ALL.

[1]  Fatih M Uckun,et al.  Protein kinase inhibitors against malignant lymphoma , 2013, Expert opinion on pharmacotherapy.

[2]  F. Uckun,et al.  Targeting Spleen Tyrosine Kinase (Syk) for Treatment of Human Disease , 2012 .

[3]  Ronald C. Chen,et al.  Revival of the abandoned therapeutic wortmannin by nanoparticle drug delivery , 2012, Proceedings of the National Academy of Sciences.

[4]  H. Kestler,et al.  Early relapse in ALL is identified by time to leukemia in NOD/SCID mice and is characterized by a gene signature involving survival pathways. , 2011, Cancer cell.

[5]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  F. Uckun,et al.  Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas , 2010, Expert review of anticancer therapy.

[7]  Victor L. J. Tybulewicz,et al.  The SYK tyrosine kinase: a crucial player in diverse biological functions , 2010, Nature Reviews Immunology.

[8]  F. Uckun,et al.  Targeting SYK kinase‐dependent anti‐apoptotic resistance pathway in B‐lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic , 2010, British journal of haematology.

[9]  Hong Ma,et al.  STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress , 2010, Proceedings of the National Academy of Sciences.

[10]  P. Ruzza,et al.  Therapeutic prospect of Syk inhibitors , 2009, Expert opinion on therapeutic patents.

[11]  L. Johnson.  Protein kinase inhibitors: contributions from structure to clinical compounds , 2009, Quarterly Reviews of Biophysics.

[12]  K. Parang,et al.  Development of Src tyrosine kinase substrate binding site inhibitors. , 2008, Current opinion in investigational drugs.

[13]  J. Okamura,et al.  CD34+CD38+CD19+ as well as CD34+CD38−CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL , 2008, Leukemia.

[14]  S. Nie,et al.  Therapeutic Nanoparticles for Drug Delivery in Cancer Types of Nanoparticles Used as Drug Delivery Systems , 2022 .

[15]  N. Heerema,et al.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.

[16]  David Steele,et al.  Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Gaynon.  Childhood acute lymphoblastic leukaemia and relapse , 2005, British journal of haematology.

[18]  F. Uckun,et al.  Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia , 2001, Oncogene.

[19]  K. L. Milkiewicz,et al.  The design, synthesis and activity of non-ATP competitive inhibitors of pp60(c-src) tyrosine kinase. Part 1: hydroxynaphthalene derivatives. , 2000, Bioorganic & medicinal chemistry letters.

[20]  Tony Pawson,et al.  Syk tyrosine kinase required for mouse viability and B-cell development , 1995, Nature.

[21]  Ramraj Choudhary,et al.  Journal of Pharmaceutics & Drug Delivery Research , 2012 .

[22]  F. Uckun.  Lipid Spheres as Attractive Nanoscale Drug Delivery Platforms for CancerTherapy , 2011 .

[23]  Rob Pieters,et al.  In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. , 2008, Cancer cell.